-
1 Comment
Yabao Pharmaceutical Group Co., Ltd is currently in a long term uptrend where the price is trading 8.3% above its 200 day moving average.
From a valuation standpoint, the stock is 84.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.5.
Yabao Pharmaceutical Group Co., Ltd's total revenue sank by 7.1% to $700M since the same quarter in the previous year.
Its net income has dropped by 53.7% to $31M since the same quarter in the previous year.
Finally, its free cash flow fell by 57.4% to $26M since the same quarter in the previous year.
Based on the above factors, Yabao Pharmaceutical Group Co., Ltd gets an overall score of 2/5.
| Exchange | SHG |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE000001CM5 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Beta | 0.16 |
|---|---|
| PE Ratio | 17.88 |
| Market Cap | 4B |
| Target Price | 10.8 |
| Dividend Yield | None |
Yabao Pharmaceutical Group Co., Ltd researches, develops, manufactures, and sells Chinese and Western medicines, and pharmaceutical packaging materials in China and internationally. The company provides pediatric products, cardiovascular and cerebrovascular products, endocrine products, women's health products, patches, and general health products. Yabao Pharmaceutical Group Co., Ltd was founded in 1978 and is based in Yuncheng, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 600351.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
